Mitsubishi Tanabe Pharma Corp (4508) - Financial and Strategic SWOT Analysis Review

  • ID: 1291974
  • SWOT Analysis
  • 57 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Tsumura & co
  • MORE
Mitsubishi Tamable Pharma Corp (4508) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Mitsubishi Tamable Pharma Corp (Mitsubishi Tamable), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tamable major brands include regicide, Simpson, steelier, credit, leapfrog, fluorite f, Nampa, alleys bi en and coinable. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe and North America. Mitsubishi Tamable is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tamable Pharma Corp Key Recent Developments

Jul 02, 2018: Mitsubishi Tamable Pharma and Osaka University co-found the Department of Neuro-Medical Science - Toward the Innovative Drug Discovery for refractory Neurological Diseases
Jul 02, 2018: Mitsubishi Tamable Pharma and Osaka University co-found the “Department of Neuro-Medical Science”
Jul 02, 2018: Mitsubishi Tamable Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds
May 30, 2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Tsumura & co
  • MORE
Section 1 - About the Company
Mitsubishi Tanabe Pharma Corp - Key Facts
Mitsubishi Tanabe Pharma Corp - Key Employees
Mitsubishi Tanabe Pharma Corp - Key Employee Biographies
Mitsubishi Tanabe Pharma Corp - Major Products and Services
Mitsubishi Tanabe Pharma Corp - History
Mitsubishi Tanabe Pharma Corp - Company Statement
Mitsubishi Tanabe Pharma Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

Section 2 – Company Analysis
Company Overview
Mitsubishi Tanabe Pharma Corp - Business Description
Product Category: Ethical Drugs
Performance
Product Category: OTC Products
Performance
Product Category: Others
Performance
Product Category: Royalty Revenue
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: North America
Performance
Geographical Segment: Others
Performance
R&D Overview
Mitsubishi Tanabe Pharma Corp - Corporate Strategy
Mitsubishi Tanabe Pharma Corp - SWOT Analysis
SWOT Analysis - Overview
Mitsubishi Tanabe Pharma Corp - Strengths
Mitsubishi Tanabe Pharma Corp - Weaknesses
Mitsubishi Tanabe Pharma Corp - Opportunities
Mitsubishi Tanabe Pharma Corp - Threats
Mitsubishi Tanabe Pharma Corp - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Mitsubishi Tanabe Pharma Corp, Recent Deals Summary

Section 5 – Company’s Recent Developments
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science - Toward the Innovative Drug Discovery for refractory Neurological Diseases
Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science”
Jul 02, 2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds
May 30, 2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
May 30, 2018: Notice Regarding Establishment of Immune-mediated Inflammatory Diseases Consortium for Drug Development
Mar 26, 2018: Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development
Dec 13, 2017: Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALS
Nov 01, 2017: Mitsubishi Tanabe Pharma: Financial Results for the First Six Months of the Fiscal year ending March 31, 2018
Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library
Sep 29, 2017: MT Pharma: Organizational Change and Personnel Change

Section 6 – Appendix
Methodology
Ratio Definitions
About
Contact Us
Disclaimer

List of Tables
Mitsubishi Tanabe Pharma Corp, Key Facts
Mitsubishi Tanabe Pharma Corp, Key Employees
Mitsubishi Tanabe Pharma Corp, Key Employee Biographies
Mitsubishi Tanabe Pharma Corp, Major Products and Services
Mitsubishi Tanabe Pharma Corp, History
Mitsubishi Tanabe Pharma Corp, Other Locations
Mitsubishi Tanabe Pharma Corp, Subsidiaries
Mitsubishi Tanabe Pharma Corp, Joint Venture
Mitsubishi Tanabe Pharma Corp, Key Competitors
Mitsubishi Tanabe Pharma Corp, Ratios based on current share price
Mitsubishi Tanabe Pharma Corp, Annual Ratios
Mitsubishi Tanabe Pharma Corp, Interim Ratios
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Mitsubishi Tanabe Pharma Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Mitsubishi Tanabe Pharma Corp, Performance Chart (2014 - 2018)
Mitsubishi Tanabe Pharma Corp, Ratio Charts
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Tsumura & co
  • Taisho Pharmaceutical Holdings Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Astellas Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll